May 26, 2013     Japanese 
  JCN 
	  Network - Home
JCN Newswire
  Home  |  Companies  | Annual Reports  |  CSR  | News Alerts     
Company
News Sectors
Automotive
Communications
Consumers
CSR
Electronics
Energy
Environment
Financial
Health & Med
Industrial
IT & Internet
Materials
Real Estate
Science & Research
Telecoms
Trade
Transportation
Departments
Annual Reports
Companies
News Alerts
News Search
Photo Gallery
Company Login
Japan Corporate News Network
About JCN
Privacy Policy
RSS  
Terms of Use
 
 
News Search

The results of your word search

Headline News

Eisai Launches Programs to Help Eliminate Lymphatic Filariasis By 2020 (Jan 31, 2012)

Eisai and Apollo Hospitals, HelpAge India to Improve Access to Medicines in India (Jan 18, 2011)

Eisai's New Sales Subsidiary in Canada (May 11, 2010)

Eisai to Sell Catheter Subsidiary to Terumo (June 19, 2008)

Takeda, Eisai Log Recurring Profit Falls in FY '07 (May 14, 2008)

Eisai Launches Sales Support Firm for Pharm. Machines in China (May 7, 2008)

M's Science and Eisai Sign Option Agreement for Sigma Agonist SA4503 (Mar 12, 2008)

Eisai Aiming to Achieve 1.5-T.-Yen Sales by FY 2016 (Mar 4, 2008)

Eisai to Buy Out U.S. Drug Maker MGI Pharma (Dec 10, 2007)

Eisai to Sell Kissei's Insulin Secretagogue in China (Sept 28, 2007)

more...
Press Release News

Eisai Announces Preclinical Research Findings Suggesting Novel Infibitory Effect on Tumor Metastasis for Anticancer Agent Halaven(R) at AACR 104th Annual Meeting (Apr 10, 2013)

Eisai Co-establishes the Global Health Innovative Technology Fund (Apr 8, 2013)

Eisai Establishes Pharma Sales Subsidiary in Moscow Ahead of Planned Direct Sales Launch in Russia (Apr 5, 2013)

Eisai to Launch Botulinum Toxin Type B Neuromuscular-Blocking Agent Nerbloc(R) intramuscular Injection 2500 Units in Japan (Mar 26, 2013)

Eisai Recieves Manufacturing and Marketing Authorization for Antiepileptic Agent Inovelon(R) in Japan (Mar 25, 2013)

Eisai Announces Launch of Chocola BB(R) Sparkling + Fiber, Containing 5 Ingredients that Help Bring Out Beauty from Within (Feb 26, 2013)

Eisai Announces Results of Phase III Study of Anticancer Agent Farletuzumab in Patients with Relapsed Platinum-Sensitive Ovarian Cancer (Jan 11, 2013)

Noblepharma and Eisai Announce Japan Lunch of Antineoplastic Agent Gliadel(R) 7.7 mg Implant (Jan 8, 2013)

Eisai Signs Agreement with Epizyme and Roche Molecular Systems to Develop Companion Diagnostic (Jan 8, 2013)

Eisai Signs Global Agreement with Fundacao Oswaldo Cruz to Begin Development of New Medicines and Vaccines for Malaria and Neglected Tropical Diseases (Oct 25, 2012)

more...
 
CSR Report Download
Most Popular


About JCN | Privacy Policy | Terms of Use | JCN Network (日本語)